Is AI Quietly Creating a GDPR Crisis in Clinical Research?
Generative AI is transforming clinical trials, but a failure to distinguish between pseudonymised and anonymised data is creating costly regulatory gaps.
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
Generative AI is transforming clinical trials, but a failure to distinguish between pseudonymised and anonymised data is creating costly regulatory gaps.
Regulatory leadership is no longer just compliance. In this episode of Chain Reaction, Dineshree Naiker explains why early regulatory strategy, supply chain governance, and value-based thinking are critical to improving patient access and healthcare outcomes.
COVID-19 exposed major weaknesses in pharmaceutical supply chains. In this episode of Chain Reaction, Trisha Pillay and Émile Malan explore how AI, regulatory reform, and local manufacturing could strengthen healthcare resilience.
By directly stimulating the visual cortex instead of relying on the retina or optic nerve, ReVision's FDA Breakthrough Device-designated implant could make vision restoration possible for millions of patients who have no existing treatment options.
Dr David Hayes explains why clinical research should be embedded early in cardiac device development and not treated as a late-stage compliance step.